3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Esophageal Neoplasms
2
Vascular Complications
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Interventions
Injections
8
pembrolizumab
4
Pemetrexed
4
Carboplatin
4
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
trifluridine tipiracil drug combination
2
sotorasib
2
fludarabine
2
Paclitaxel
2
Drug Therapy
2
Docetaxel
2
Bevacizumab
2
zimberelimab
1
trametinib
1
toripalimab
1
tislelizumab
1
sacituzumab govitecan
1
netrin-1 inhibitor NP137
1
cemiplimab
1
WW Domain-Containing Oxidoreductase
1
SYS6006 COVID-19 vaccine
1
Panitumumab
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Etoposide
1
Cyclophosphamide
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumors
×
Immune Checkpoint Inhibitors
×
90 days
×
Clear all
NCT06819735
2026-05-06
DOMISOL
Domain Therapeutics SA
Phase 1/2
Recruiting
125 enrolled